Nevirapine Triple Combination: Preliminary Results Released Nov. 17

var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www."); document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E")); ion" CONTENT="Preliminary results of a study of the convergent combination approach to antiviral treatment were released in November. The subjects--who had at least six months prior treatment with AZT , ddI, or ddC--randomly received AZT and ddI, or AZT plus ddI plus nevirapine. Nevirapine is an experimental HIV treatment that, whe"> Nevirapine Triple Combination: Preliminary Results Released Nov. 17 < > // var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www."); document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E")); > < > // var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www."); document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E")); >

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Nevirapine Triple Combination: Preliminary Results Released Nov. 17

AIDS Treatment News (11/18/94) No. 211, P. 6
James, John S.

Preliminary results of a study of the "convergent combination" approach to antiviral treatment were released in November. The subjects--who had at least six months prior treatment with AZT, ddI, or ddC--randomly received AZT and ddI, or AZT plus ddI plus nevirapine. Nevirapine is an experimental HIV treatment that, when used alone, has a very strong anti-HIV effect initially but one that diminishes as the virus develops resistance to the drug. After 48 weeks, the researchers found that patients who received all three drugs had 25 percent higher T-helper counts than those who only received AZT and ddI. The ineffectivity of peripheral blood mononuclear cells (PBMCs) was reduced by 50 percent more in the triple combination group. There were no indications of survival or disease-progression benefit for those who received the triple combination. Seventeen percent of those participants died or experienced HIV disease progression. The triple combination also produced more side effects than only AZT and ddI. In a commentary, AIDS Treatment News concluded that the results suggest the necessity of more flexible research strategies, with many small, rapid trials to quickly assess promising leads.

941221
AD942281

Copyright © 1994 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .